Medicare PET/Alzheimer’s Disease Policy Criticized By Private Payor Group
This article was originally published in The Gray Sheet
Executive Summary
America's Health Insurance Plans opposes CMS' tentative decision to narrowly cover PET for Alzheimer's disease diagnosis, citing inadequate evidence
You may also be interested in...
Medicare Will Cover PET To Distinguish Alzheimer’s From Other Dementia
CMS' decision to provide national coverage of FDG-PET imaging for some suspected dementia patients corresponds with the Neuroimaging Work Group of the Alzheimer's Association's consensus position
PET Alzheimer’s Coverage Faces Uphill Battle Following AHRQ Report
A second 1AHRQ tech assessment finding insufficient evidence for PET in diagnosing Alzheimer's disease casts further doubt that CMS will reverse its national non-coverage policy for the indication
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.